“…Continuing this theme into immunology, Mataraza and Gotwals reviewed the current status of immunotherapy in urological cancers. Durable responses to immunotherapy in metastatic melanoma have revolutionised this approach to cancer therapy, but as stated, there remains a significant challenge in finding biomarkers to predict responses (some of these drugs have moderate‐to‐severe toxicity risk), as well as combined therapies to combat drug resistance.…”